Recap: Epizyme Q3 Earnings

Shares of Epizyme EPZM remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 37.50% year over year to ($0.55), which beat the estimate of ($0.60).

Revenue of $3,566,000 decreased by 37.60% year over year, which missed the estimate of $5,430,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 06, 2020

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/7y95p5e9

Recent Stock Performance

Company's 52-week high was at $27.82

52-week low: $11.03

Price action over last quarter: Up 3.99%

Company Profile

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing & commercializing novel epigenetic medicines. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL), Phase II clinical trial for relapsed or refractory patients with mesothelioma, Phase I dose-escalation and expansion study for children with INI1-negative solid tumors. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias & PRMT5 inhibitor.